Shares of TYK MEDICINES-B (02410) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76 million.

The catalyst for the move was news from the 2026 ASCO conference, where the company presented interim analysis results from the ESAONA study in a Late-Breaking Abstract oral presentation. The study focused on its drug edotinib (TY-9591) as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients with brain metastases.

An analysis highlighted that edotinib demonstrated superiority over osimertinib in a head-to-head trial for NSCLC patients with brain metastases. The drug is anticipated to be launched in the third quarter of 2026.

Product Differentiation and Market Potential

Previous research reports have noted that TY-9591 is the only third-generation EGFR-TKI globally to have conducted a head-to-head trial against osimertinib. The drug's development program also includes targeting the EGFR L858R mutation and exploring its use in combination with chemotherapy for first-line treatment of advanced NSCLC, expanding its potential beyond brain metastasis.

Projected Financial Impact

Forecasts suggest that TY-9591 could achieve peak sales exceeding 5 billion yuan under a neutral scenario. Revenue for the company over the next three years is expected to be primarily driven by the contributions from TY-9591.